Longevity Health Holdings Inc. (XAGE) Soars 15% on $59M THPlasma Merger

Longevity Health Holdings Inc. (NASDAQ: XAGE) has announced a definitive merger agreement with THPlasma, a leading player in the plasma collection industry, in an all-stock transaction valued at $59 million plus $20 million in earnouts. The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare, creating a potentially synergistic portfolio given Carmell's focus on plasma-derived growth factors.

THPlasma, a profitable plasma collection company, is expanding from 2 centers in FY24 to 5 centers in FY25, with guaranteed sales agreements worth $100 million annually. The company projects FY2025 revenue of $10 million and expects significant growth to $32 million in FY2026. The combined company will continue trading as XAGE, with THPlasma's George Chi becoming Co-Chairman and CEO. Simultaneously, Longevity announced the termination of its planned 20/20 BioLabs transaction. The merger is expected to close in Q4 2025.

This merger strategically positions Longevity in the plasma collection industry, which faces supply challenges despite the United States providing 60% of global plasma. THPlasma's expansion from 2 collection centers to 5, with $100 million in guaranteed sales agreements, represents significant operational momentum in addressing this market gap. The merger is expected to drive further growth in THPlasma through M&A and organic growth, benefiting Longevity's shareholders.